Gene Therapy Analytical Development Europe


  • 25-05-2021 to 27-05-2021
  • 08:00 - 17:00
  • GBP 1749.00 - GBP 3046.00
  • Share

In the context of unprecedented gene therapy investment and clinical progress, with mounting regulatory scrutiny, Gene Therapy Analytical Development Europe will unite innovative biotech and pharma organisations to develop robust analytical tools to guarantee the consistency, quality, and safety of gene therapy products.

Whether you’re looking for specific characterisation, potency or infectivity approaches to improve your current analytical toolbox or if you’re seeking to understand how gene therapy analytics differ from other biologics you’ve worked on in the past, this focused, technical event will provide insights specifically on the unique analytical challenges posed by gene therapy vectors, delivered by ‘boots on the ground’ scientists grappling with these challenges first-hand.

Join 150+ analytical pioneers to discover the realities of working with tools like dPCR, AUC and HPLC, as well as how and where these tools can be most effective in process development, and what the European regulators expect in order to grant approval. Whether you’re working with AAV or lentiviral vectors, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development.

FULL ACCESS PASS: Conference + 3 Workshops OR Pre-Conference Day - Drug Developer Pricing GBP 2464.00
Conference Only - Drug Developer Pricing GBP 1749.00
FULL ACCESS PASS: Conference + 3 Workshops OR Pre-Conference Day - Standard Pricing GBP 3046.00
Conference Only - Standard Pricing GBP 1999.00


Category: Conferences | Science, Health & Medicine | Pharmaceuticals

Speakers: Kristin Acker, Senior Scientist Analytical, Development Takeda, Ian Anderson, Associate Director Analytical Sciences, Allergan, Barbara Bonamassa, Quality Assessor & European Medicines Agency (EMA) Expert for ATMPs, Italian Medicines Agency (AIFA), George Bou-Assaf, Analytical Development Team Leader, Biogen, Christopher Bravery, Consulting Regulatory Scientist, Consulting on Advanced Biologicals, Sofia Carvalho, Senior Research Associate, IBET, Eric Devine, Quality Control, University of Nantes, David Dobnik, Senior Research Associate, National Institute of Biology, Fabien Dorange, Head of Analytical CMC, Genethon, Uditha DeAlwis, Executive Director, Sarepta Therapeutics, Anne Douar, Chief Development Officer, Vivet Therapeutics, Cecilia Della Vale, Associate Director Analytical Science, PTC Therapeutics, Alan Griffith, Associate Director, Meira Gene Therapies, Christina Grigoriadou, Senior Scientist, AstraZeneca, Matt Hankinson, Associate Director, Allergan, Santosh Khatwani, Associate Director Analytical Development, Sangamo, Stephen Kaminsky, Professor of Research in Genetic Medicine Associate Director, Weill Cornell Medical College, Francesco Lanucara, Analytical Development & CMC, Allergan, Hannah Mahenko, Scientist, Sanofi, Tushar Patel, Senior Scientist, bluebird bio, Robert Pletzanauer, Head of Process Analytics, Takeda, Magalie Penaud Budloo, Research Scientist, University of Nante, Roland Pach, Project Lead Analytical Technical, Roche, Lyndi Rice, Head of QC, BioMarin, Nasser Sadr, Associate Director, UniQure, Stuart Taylor, Analytical Development Scientist, Gyroscope, Connie Tsai, Senior Scientist Analytical Development, Novartis Gene Therapies, Jaap Twisk, Senior Director Analytical Development, UniQure, Tomasz Witkos, Bioassay Scientist, AstraZeneca, Eric Yearly, Principal Scientist, Bridge Bioscience